Research led by the Dana Farber Cancer Institute, Massachusetts, performed a secondary analysis of the Dana-Farber Cancer Institute 05-043 trial. In the paper, "Risk of Short-Term Prostate-Specific Antigen Recurrence and ...
Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy. However, despite the benefits of this therapy, ...
Jun 15, 2022
0
84
Male sex hormones interfere with the body's ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study co-led by a Cedars-Sinai Cancer investigator.
Jun 10, 2022
0
61
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients' ...
May 26, 2022
0
73
Patients receiving radiotherapy to treat high-risk prostate cancer also benefit from androgen deprivation therapy. The ideal duration of treatment may be roughly two years if receiving external beam radiation and one year ...
Feb 28, 2022
0
53
Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs ...
Feb 18, 2022
0
79
The standard treatment for advanced metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). And even if this is efficient in the short term, 1/3 of PCa will become resistant to ADT and develop castration-resistant ...
Mar 29, 2021
0
88
The standard treatment for men with advanced prostate cancer is androgen-deprivation therapy. Androgens are hormones that fuel prostate cell growth; removing them with either drugs or surgery causes the prostate gland to ...
May 1, 2020
0
237
Scientists are constantly looking for new ways to improve cancer treatment, particularly for aggressive tumours. But spotting which cancers are aggressive when they're first diagnosed can be tough, particularly in prostate ...
Mar 20, 2019
0
233
Adding a new anti-hormonal drug to the standard treatment for advanced prostate cancer has been shown to reduce the risk of dying by almost 40 percent, according to two studies published Saturday.
Jun 3, 2017
1
63
